Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:FATE
Raised
Post IPO Valuation

General Information

Websitefatetherapeutics.com
Twitter@FateTherapeuti
CategoryBioTech
Employees
Founded2007
DescriptionStem Cell Biology Therapeutics

Offices

La Jolla, USA
10931 North Torrey Pines Road
Suite 107
La Jolla, CA, 92037
USA

People

Co-founder
Co-Founder
Co-Founder
Co-Founder
Co-founder
Co-Founder
Co-Founder, Founding Entrepreneur
CTO
Show All People

Funding

TOTAL $57.2M
FUNDING TOTAL $57.2M
Series A, 11/2007
ARCH Venture Partners
Polaris Partners
Venrock
OVP Venture Partners
$12M
Series B, 5/2011
OVP Venture Partners
Astellas Venture Management
Genzyme Ventures
ARCH Venture Partners
Polaris Partners
Venrock
$36M
Venture Round, 8/2012
$9.2M
DEBT TOTAL $21M
Debt, 4/2011
$1M
Debt, 8/2013
$20M

Tags

Fate Therapeutics

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.

The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

Recent Milestones

Videos

Screenshots

Fate Therapeutics screenshot
Above: Home Page
Uploaded: 3/13/10

Stock Price

Sources

  1. Puget Sounds Business Journal (seattle.bizjournals.com) [edit]
  2. SEC (sec.gov) [edit]
  3. SEC (sec.gov) [edit]
  4. Fate Therapeutics raises $9.2M for stem cell treatments (nctimes.com) [edit]
  5. Fate Therapeutics Nets Venture Capital Debt (venturedeal.com) [edit]
  6. Fate Therapeutics, founded by stem cell experts, targets $69M IPO (fiercebiotech.com) [edit]
Edit This Page
Last Edited 3/31/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy